CV Sciences, Inc.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
CVSIStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Product sales, net | $3,195 | $3,606 |
| Cost of goods sold | 1,633 | 1,948 |
| Gross profit | 1,562 | 1,658 |
| Operating expenses: | ||
| Research and development | 18 | 30 |
| Selling, general and administrative | 1,862 | 2,139 |
| Benefit from reversal of accrued payroll taxes (Note 11) | — | (522) |
| Total operating expenses | 1,880 | 1,647 |
| Operating income (loss) | (318) | 11 |
| Gain on extinguishment of debt | (20) | (38) |
| Change in fair value of convertible notes | 252 | — |
| Interest expense, net | 93 | 151 |
| Loss before income taxes | (643) | (102) |
| Income tax expense | — | 7 |
| Net loss | $(643) | $(109) |
| Weighted average common shares outstanding, basic and diluted | 186,920 | 184,264 |
| Net loss per common share, basic and diluted | $(0.00) | $(0.00) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.